CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (118)	4/24/1997 8:08:00 AM
From: Howard Frederick	of 675

Following is a hot link to an abstract Rick Harmon posted to the NTII thread April 3. The abstract is about a paper published by Stuart Lipton and is titled "Similarity of neuronal cell injury and death in AIDS dementia and focal cerebral ischemia: potential treatment with NMDA open-channel blockers and nitric oxide-related species." exchange2000.com I don't know if you have read the abstract or the paper, but I would be interested in your reaction to it. Particularly interesting would be your reaction to the statements "A final common pathway for neuronal susceptibility appears to be operative, similar to that observed in stroke and several neurodegenerative diseases. This mechanism involves excessive activation of N-methyl-D-aspartate (NMDA) receptor-operated channels ..." For what it is worth, I have not read the paper. Also, out of curiosity, it appears you have specific knowledge of the patents filed by Dr. Lipton. I don't. Do you think it likely he would file additional patents when he feels it may have use vs. stroke? Apologies to CNSI readers, but given the competitive situation between CNSI and NTII, I would think this topic would be of interest to shareholders of both. I own shares of NTII.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next